南微医学公告，2025年4月22日至2025年10月21日期间，公司通过集中竞价交易方式回购股份，实际回 购股数为33.51万股，占总股本的0.18%，回购价格区间为62.01元/股至93.76元/股，使用资金总额为 3002.15万元。此次回购的股份将用于员工持股计划或股权激励。 ...

Market Overview - The medical device sector experienced a decline of 1.35% on October 13, with Nanwei Medical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Top Performers - Zhendemedical (603301) saw a closing price of 60.44, with a rise of 7.05% and a trading volume of 166,300 shares [1] - Wuzhou Medical (301234) closed at 46.22, up 6.13%, with a trading volume of 32,400 shares [1] - BGI Genomics (688114) closed at 72.35, increasing by 4.99% with a trading volume of 89,300 shares [1] Underperformers - Nanwei Medical (688029) closed at 91.15, down 6.78% with a trading volume of 42,800 shares [2] - Kangzhong Medical (688607) closed at 26.57, down 4.60%, with a trading volume of 25,700 shares [2] - Mindray Medical (300760) closed at 235.20, down 2.81%, with a trading volume of 108,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 412 million yuan from institutional investors, while retail investors contributed a net inflow of 325 million yuan [2][3] - The top net inflow from retail investors was observed in Mindray Medical, with 2.63 million yuan, while Zhendemedical experienced a net outflow of 55.19 million yuan from retail investors [3]

一次性胆道镜优势 内容概要：胆道镜是一种通过微创方式进入胆道内进行检查和治疗的医疗设备，通过胆道镜直接观察胆 管内的病变情况，进行活检、取石、扩张狭窄等操作，大大提高了胆道疾病的诊断和治疗效率。胆道镜 可分为一次性及可重复使用。与传统可重复使用胆道镜相比，一次性胆道镜拥有更大的工作孔道、更细 的镜身，更易通过狭窄段，且易于部署、使用，一次性使用防止交叉感染风险。一次性胆道镜高清图像 质量可以使医生直接观察病变，而其纤细的外径使医生可以轻松处理曾经是消化道最后一个盲区的肝内 胆管和胆囊病变，同时还拥有更大的工作通道，可以使用更多器械开展各种镜下治疗。近年来，全球一 次性胆道镜市场规模不断扩张，由2018年的1.64亿美元增长至2024年的4.16亿美元，期间实现年复合增 长率16.8%。中国市场，随着一次性内镜的技术不断进步和成本的不断下降，越来越多的医疗机构已经 开始认可和采用一次性内镜，包括胆道镜、支气管镜、输尿管镜、鼻咽镜等。带动中国一次性胆道镜市 场规模由2018年的0.12亿元增长至2024年的0.88亿元，实现年复合增长率39.9%，增幅远高于全球市 场。中国一次性胆道镜行业处于发展初期阶段，布局企 ...

Core Points - Nanwei Medical announced that as of September 30, 2025, the company has repurchased a total of 109,797 shares, which represents 0.0585% of the total share capital [2] Summary by Category - **Share Repurchase** - The company has not repurchased any shares since September 2025 [2] - The total number of shares repurchased to date is 109,797 [2] - The repurchased shares account for 0.0585% of the company's total share capital [2]

Core Viewpoint - Nanwei Medical (688029.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Summary by Categories Share Buyback Details - As of September 30, 2025, the company has repurchased a total of 109,797 shares, which represents 0.0585% of the total share capital [1] - The highest purchase price for the shares was 93.76 yuan per share, while the lowest was 62.01 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees such as stamp duty and commissions, is 9,604,989.12 yuan [1]

Group 1 - Company Nanwei Medical (SH 688029) announced on October 9 that as of September 30, 2025, it has repurchased approximately 110,000 shares, accounting for 0.0585% of the total share capital, with a total expenditure of about 9.6 million yuan [1] - The highest purchase price for the repurchased shares was 93.76 yuan per share, while the lowest was 62.01 yuan per share [1] - For the year 2024, the revenue composition of Nanwei Medical is 99.49% from medical devices and 0.51% from other businesses [1] Group 2 - As of the time of reporting, the market capitalization of Nanwei Medical is 18.4 billion yuan [2]

证券代码：688029 证券简称：南微医学 公告编号：2025-043 南微医学科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/22，由董事长隆晓辉先生提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 | 4 | 22 | 日~2025 | 年 | 10 | 21 | 日 | | 预计回购金额 | 3,000万元~5,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 109,797股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.0585% | | | | ...

两融数据显示，该股最新融资余额为2.15亿元，近5日减少1016.97万元，降幅为4.52%。 据天眼查APP显示，南微医学科技股份有限公司成立于2000年05月10日，注册资本18784.7422万人民 币。（数据宝） 南微医学9月30日大宗交易平台共发生2笔成交，合计成交量15.00万股，成交金额1505.26万元。成交价 格均为100.35元。 证券时报·数据宝统计显示，南微医学今日收盘价为100.35元，上涨7.52%，日换手率为2.24%，成交额 为4.14亿元，全天主力资金净流入2030.61万元，近5日该股累计上涨11.70%，近5日资金合计净流入 248.35万元。 | 成交量 （万股） | 成交金额 （万元） | 成交价格 （元） | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 7.50 | 752.63 | 100.35 | 0.00 | 招商证券股份有限公司北京 | 广发证券股份有 | | | | | | 景辉街证券营业部 | 限公司总部 | | 7.50 | 752.63 | 100.3 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第2笔成交价格为100.35元，成交7.50万股，成交金额752.63万元，溢价率为0.00%，买方营业部为招商 证券股份有限公司北京景辉街证券营业部，卖方营业部为广发证券股份有限公司总部。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1505.26万元。该股近5个交易日累 计上涨11.74%，主力资金合计净流入1896.76万元。 责任编辑：小浪快报 第1笔成交价格为100.35元，成交7.50万股，成交金额752.63万元，溢价率为0.00%，买方营业部为招商 证券股份有限公司北京景辉街证券营业部，卖方营业部为广发证券股份有限公司总部。 9月30日，南微医学收涨7.52%，收盘价为100.35元，发生2笔大宗交易，合计成交量15万股，成交金额 1505.26万元。 ...

Group 1 - On September 30, Nanwei Medical executed a block trade of 150,000 shares, with a transaction amount of 15.0526 million yuan, accounting for 3.51% of the total transaction volume for the day [1] - The transaction price was 100.35 yuan, which was in line with the market closing price of 100.35 yuan [1] Group 2 - The trading date for the transaction was September 30, 2025, with the stock code 688029 for Nanwei Medical [2] - The transaction amount was recorded at 752.63 million yuan, with a trading volume of 7.5 [2]